Enhancement of trail/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells

International Journal of Cancer

Volumn 104, Issue 4, 2003, Pages 409-417

  Wu, Xiu Xian ^a   Kakehi, Yoshiyuki ^a   Mizutani, Youichi ^b   Nishiyama, Hiroyuki ^c   Kamoto, Toshiyuki ^c   Megumi, Yuzuru ^c   Ito, Noriyuki ^c   Ogawa, Osamu ^c  

^a KAGAWA UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

ADR; Apoptosis; DR4; DR5; RCC; TRAIL

Indexed keywords

ACETYLASPARTYLMETHIONYLGLUTAMINYLASPARTALDEHYDE; ACETYLISOLEUCYLGLUTAMYLTHREONYLASPARTALDEHYDE; ACETYLLEUCYLGLUTAMYLHISTIDYLASPARTALDEHYDE; BENZYLOXYCARBONYLTRYPTOPHYLGLUTAMYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 10; CASPASE 3; CASPASE 6; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; DNA FRAGMENT; DOXORUBICIN; FAS LIGAND; FC RECEPTOR; HLA DR4 ANTIGEN; HLA DR5 ANTIGEN; HYBRID PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; KIDNEY CARCINOMA; PRIORITY JOURNAL; STUDENT T TEST; WESTERN BLOTTING;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, RENAL CELL; CASPASES; DOXORUBICIN; DRUG SYNERGISM; HUMANS; KIDNEY NEOPLASMS; MEMBRANE GLYCOPROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037457474     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10948     Document Type: Article

References (45)

1. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000;27:177-86.
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
3. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
4. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90.
5. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998;161:2833-40.
6. Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH, Smith CA, Goodwin RG, Kubin MZ. Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 1999;162:2597-605.
7. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubir M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63.
8. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A. DeForge L, Koumenis IL, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
9. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-3.
10. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8.
11. Mariani SM, Matiba B, Armandola EA, Krammer PH. Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J Cell Biol 1997;137:221-9.
12. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997;89:1845-53.
13. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin KM. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 1997;90:3118-29.
14. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999;59:734-41.
15. Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999;59:6153-8.
16. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang H-JS. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000;60:847-53.
17. Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M, Findlay DM. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 2002;99:491-504.
18. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000;6:564-7.
19. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7:383-5.
20. Wu XX, Mizutani Y, Kakehi Y, Yoshida O, Ogawa O. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells. Cancer Res 2000;60:2912-8.
21. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-9.
22. Wu XX, Mizutani Y, Kakehi Y, Nakamura E, Mitsumori K, Takahashi, T, Terachi T, Okada Y, Yoshida O. Expression of major histocompatibility complex antigens and adhesion molecules on renal cell carcinoma cells and effect of interferon-α and/or cimetidine on the expression. Acta Urol Jpn 1998;44:621-6.
23. Wilson PD, Dillingham MA, Breckon R, Anderson RJ. Defined human renal tubular epithelia in culture: growth, characterization and hormonal response. Am J Physiol 1985;248:F436-3.
24. Mizutani Y, Wu XX, Yoshida O, Shirasaka T, Bonavida B. Chemoimmunosensitization of the T24 human bladder cancer line to Fasmediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil. Oncol Rep 1999;6:979-82.
25. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol 1992;119:493-501.
26. Murai N, Ueba T, Takahashi JA, Yang HQ, Kikuchi H, Hiai H, Hatanaka M, Fukumoto M. Apoptosis of human glioma cells in vitro and in vivo induced by a neutralizing antibody against human basic fibroblast growth factor. J Neurosurg 1996;85:1072-7.
27. Wu XX, Kakehi Y, Mizutani Y, Lu JJ, Terachi T, Ogawa O. Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil. Int J Oncol 2001;19:19-24.
28. Koizumi H, Ohkawa I, Tsukahara T, Momoi T, Nakada K, Uchikoshi T. Apoptosis in favourable neuroblastomas is not dependent on Fas (CD95/APO-1) expression but on activated caspase 3 (CPP32). J Pathol 1999;189:410-5.
29. Wu XX, Kakehi Y, Mizutani Y, Terachi T, Ogawa O. Increased intracellular doxorubicin by anti-FAS monoclonal antibody: a mechanism that enhances the cytotoxicity in renal cell carcinoma cells. Urology 2001;57:993-8.
30. Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 2001;61:759-63.
31. Berenbaum MC. Synergy, additivism and antagonism in immunosuppression. Clin Exp Immunol 1977;28:1-18.
32. Berenbaum MC. A method for testing for synergy with any number of agents. J Infect Dis 1978;137:122-30.
33. Griffith TS, Fialkov JM, Scott DL, Azuhata T, Williams RD, Wall NR, Altieri DC, Sandler AD. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res 2002;62:3093-9.
34. Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer 2002;38:167-76.
35. Ashkenazi A. Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8.
36. Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, Takase K, Moriyama M, Nakano T, Suzuki A. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 2000;32:482-90.
37. Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 2000;96:3900-6.
38. Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000;20:205-12.
39. Thomberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-6.
40. Nunez G, Benedict MA, Hu Y, Inohara N. Caspases: the proteases of the apoptotic pathway. Oncogene 1998;17:3237-45.
41. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J. Tschopp J. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000;2:241-3.
42. Seol DW, Li J, Seol MH, Park SY, Talanian RV, Billiar TR. Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. Cancer Res 2001;61:1138-43.
43. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 2001;61:1645-51.
44. Slee EA, Zhu H, Chow SC, MacFarlane M, Nicholson DW, Cohen GM. Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD.FMK) inhibits apoptosis by blocking the processing of CPP32. Biochem J 1996:315:21-4.
45. Chabner BA, Longo DL. Cancer chemotherapy and biotherapy, 2nd ed. Philadelphia: Lippincott-Raven, 1996. 297-332.